Introduction
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and comprises up to 80% of the malignancies arising from thyroid follicular cells. 1, 2) Papillary thyroid microcarcinoma (PTMC) is defined by the World Health Organization (WHO) as a PTC measuring ≤10 mm in the greatest dimension.
Most PTMC are not detectable upon physical examination. 3) The increased use of thyroid ultrasonography and technical improvements associated with fine-needle aspiration biopsy (FNAB) have resulted in rapidly increase in the rate of PTMC patients. 4, 5) It is estimated that PTMC accounts for up to 30% of total PTC. 6, 7) In South Korea, the incidence of PTMC patients have increased markedly over the past 5 years. 8) PTC patients show a variety clinical courses and long-term outcomes. In general, PTC has a good prognosis with a 5-year survival rate of 97-99% and 10-year survival rate of 98%. 1, 9) Similarly, most PTMC have excellent prognosis. However, some studies have shown loco-regional recurrence, distant metastasis, and mortality. 7, 10, 11) One study suggested that In the present study, we investigated the difference of clinicopathologic features in PTMC according to age. We hypothesized that older patients were not associated with unfavorable features in PTMC.
Materials and Methods

Patients
We reviewed the records of 1415 patients who underwent total thyroidectomy for PTC between January Table 1 summarizes the baseline characteristics of 
Results
Discussion
According to staging systems, age is one of the most powerful prognostic factors. Older age is identi-fied a poor prognostic factor for PTC patients. Previous studies showed that older patients had aggressive features than young patients. 14) Ito et al. 14) showed that lymph node recurrence was high and survival was poor in patients older than 60 years. The age criterion varies according to classification systems: 45 years in the UICC TNM classification, 3) 41 years for males and 51 years for females in the Age, Metastasis, Extent, and Size (AMES) classification, 15) and 50 years in the Cancer Institute Hospital (CIH) classification. 16 18) reported that there was no association between age and subclinical central lymph node metastasis in PTMC. This result is consistent with our report and some other studies. [18] [19] [20] The coexistence of PTC and Hashimoto's thyroiditis has been reported to range from 10% to 58%. 21) The coexistence of Hashimoto's thyroiditis with PTC is associated with a better outcome. 22, 23) A previous study reported that patients with PTC and lymphocytic thyroiditis had a good prognosis. The authors reported lower frequencies of extrathyroidal extension, nodal metastasis, and distant metastasis. 24) Kim et al. 21) suggested that coexisting Hashimoto's thyroiditis in patients with PTC is a negative predictive factor for central lymph node metastasis. However, other studies showed that coexistence of Hashimoto's thyroiditis has no protective effect on prognosis. 25 PTC is frequently multifocal. Shattuck et al. 26) suggested that multifocality is not a manifestation of intraglandular metastasis. Multifocal tumors in PTC are the result of the generation of multiple independent origins.
Multifocality of PTC was considered a significant prognostic factor. Multifocality has been associated with increased lymph node and distant metastasis, persistence residual disease after initial treatment, and recurrence. 26) Similarly, multifocality in PTMC is associated with lymph node metastasis and capsular invasion. 7, 27) Patients with multifocality should receive aggressive treatment. 28) Multifocality in PTMC is not unusual. 17) In this study, the incidence of multifocality was 24.8%. The incidence of multifocality in PTMC has been reported to be 19 to 32%.
17)
The presence of a BRAF V600E mutation has been a more aggressive and poor clinical course. A prior study reported that BRAF V600E mutation was associated with advanced tumor stage and metastasis in PTC. 29 There has been debate whether PTMC patients should be managed as aggressively as other PTC patients. In our institution, total thyroidectomy is the preferred option. One study suggested that observation only without treatment is safe for small intrathyroidal PTMCs. 6) Other authors favor lobectomy 6) while yet other authors prefer total thyroidectomy, I-131 whole body scan, and thyroid stimulating hormone (TSH) suppressive therapy. 30) No prospective and randomized clinical trials have been performed to determine the proper treatment for PTMC.
In this study, there was no statistically significant difference of clinicopathologic features between groups.
We consider that if old age is a poor prognostic factor in PTMC, they have aggressive clinicopathologic characteristics at the time of diagnosis or initial surgery. However, we concludes that old age itself is not associated with unfavorable clinicopathologic features in PTMC. There was no significant difference in the stage older than 45 years. However, long-term follow-up is needed to observe the recurrence and survival.
